| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1570-0232(02)00486-5 |
| P698 | PubMed publication ID | 12450521 |
| P50 | author | Pedro Dorado | Q41704704 |
| Adrián Llerena | Q56419301 | ||
| P2093 | author name string | Antonio González | |
| Roland Berecz | |||
| Alfredo de la Rubia | |||
| Macarena Cáceres | |||
| María Jesús Norberto | |||
| P2860 | cites work | Clinical pharmacokinetics of fluoxetine | Q28254262 |
| Effect of the CYP2C19 oxidation polymorphism on fluoxetine metabolism in Chinese healthy subjects | Q28343864 | ||
| Pharmacokinetics of selective serotonin reuptake inhibitors | Q33837768 | ||
| Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? | Q33896174 | ||
| Patterns of drug treatment of schizophrenic patients in Estonia, Spain and Sweden | Q34347657 | ||
| Inhibition by fluoxetine of cytochrome P450 2D6 activity. | Q34363744 | ||
| The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin | Q34409085 | ||
| Interethnic differences in drug metabolism: influence of genetic and environmental factors on debrisoquine hydroxylation phenotype | Q41138049 | ||
| Determination of fluoxetine and norfluoxetine in human plasma by high-pressure liquid chromatography with fluorescence detection | Q42537408 | ||
| Serum concentrations of fluoxetine in the clinical treatment setting | Q43569301 | ||
| Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe | Q43576840 | ||
| Determination of clozapine and its N-desmethyl metabolite by high-performance liquid chromatography with ultraviolet detection | Q43630883 | ||
| High-performance liquid chromatographic method to screen and quantitate seven selective serotonin reuptake inhibitors in human serum. | Q43756813 | ||
| Use of the Mesoridazine/Thioridazine Ratio as a Marker for CYP2D6 Enzyme Activity | Q57585972 | ||
| Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers | Q57586060 | ||
| Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine | Q59915077 | ||
| Determination of the antidepressant fluoxetine in human plasma by LC with UV detection | Q63301811 | ||
| Simultaneous determination of fluoxetine and norfluoxetine enantiomers in biological samples by gas chromatography with electron-capture detection | Q67590320 | ||
| The stereospecific determination of fluoxetine and norfluoxetine enantiomers in human plasma by high-pressure liquid chromatography (HPLC) with fluorescence detection | Q67882547 | ||
| Serum fluoxetine and norfluoxetine concentrations and antidepressant response | Q69738517 | ||
| Determination of fluoxetine and norfluoxetine in human plasma by capillary gas chromatography with electron-capture detection | Q70722970 | ||
| Human cytochromes mediating N-demethylation of fluoxetine in vitro | Q73701071 | ||
| The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine | Q77341197 | ||
| P4510 | describes a project that uses | high-performance liquid chromatography | Q381233 |
| P433 | issue | 1 | |
| P921 | main subject | fluoxetine | Q422244 |
| P304 | page(s) | 25-31 | |
| P577 | publication date | 2003-01-01 | |
| P1433 | published in | Journal of Chromatography B Analytical Technologies in the Biomedical and Life Sciences | Q2422407 |
| P1476 | title | Determination of fluoxetine and norfluoxetine in human plasma by high-performance liquid chromatography with ultraviolet detection in psychiatric patients | |
| P478 | volume | 783 |
| Q41821006 | A novel chiral GC/MS method for the analysis of fluoxetine and norfluoxetine enantiomers in biological fluids. |
| Q51537199 | A validated microfluidics-based LC-chip-MS/MS method for the quantitation of fluoxetine and norfluoxetine in rat serum. |
| Q58135788 | Determination of Fluoxetine in Human Plasma by Liquid Chromatography–Mass Spectrometry and Its Application |
| Q51762643 | Dispersive liquid-liquid microextraction combined with acetonitrile stacking through capillary electrophoresis for the determination of three selective serotonin reuptake inhibitor drugs in body fluids. |
| Q44730960 | Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions. |
| Q50475979 | Effect of CYP2D6, CYP2C9 and ABCB1 genotypes on fluoxetine plasma concentrations and clinical improvement in children and adolescent patients. |
| Q37737291 | Efficacy, safety and tolerability of Symbyax for acute-phase management of treatment-resistant depression |
| Q92376577 | Emergence of Fluoxetine-Resistant Variants during Treatment of Human Pancreatic Cell Cultures Persistently Infected with Coxsackievirus B4 |
| Q45078060 | Impact of fluoxetine on liver damage in rats |
| Q51736030 | Optimization of alcohol-assisted dispersive liquid-liquid microextraction by experimental design for the rapid determination of fluoxetine in biological samples. |
| Q58308207 | Polypropylene-Based Microextraction Method for Determination of Fluoxetine in Human Urine Samples |
| Q40530871 | Protective Effects of Caffeic Acid Phenethyl Ester on Fluoxetine-Induced Hepatotoxicity: An Experimental Study |
| Q36757571 | Selective serotonin reuptake inhibitor fluoxetine inhibits replication of human enteroviruses B and D by targeting viral protein 2C. |
| Q41430746 | Simultaneous determination of olanzapine and fluoxetine hydrochloride in capsules by spectrophotometry, TLC-spectrodensitometry and HPLC. |
Search more.